Portage Biotech is a clinical stage immune-oncology company focused on overcoming immune resistance. Co. sources, nurtures and develops therapies for a variety of cancers, by funding, implementing product development strategies, clinical counsel/trial design, shared services, financial and project management to enable execution of commercially informed development plans. Co.'s drug development pipeline portfolio encompasses products or technologies based on biology addressing known resistance pathways/mechanisms of check point inhibitors with scientific rationales, including intratumoral delivery, nanoparticles, liposomes, aptamers, and virus-like particles. The PRTG YTD return is shown above.
The YTD Return on the PRTG YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether PRTG YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PRTG YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|